Search
for
Sort by
Research
270-300 / 1000+ resultsresearch PD49-02 MEDICATIONS MOST COMMONLY ASSOCIATED WITH ERECTILE DYSFUNCTION: EVALUATION OF THE FOOD AND DRUG ADMINISTRATION NATIONAL PHARMACOVIGILANCE DATABASE
Certain medications, especially 5-alpha reductase inhibitors, are commonly linked to erectile dysfunction.
research Organizadores e cortadores de comprimidos: riscos e restrições ao uso
Pill organizers and cutters can help with taking medication regularly but may affect the medication's effectiveness and safety.
research Sexual adverse events-related to dutasteride e finasteride: analysis of real-life data from Eudra-Vigilance database
research Assessing the safety of topical minoxidil through disproportionality analysis of FAERS reports
Topical minoxidil may cause more side effects than currently listed, needing updated safety information.
research Suspected adverse reactions to medications and food supplements containing Serenoa repens: A worldwide analysis of pharmacovigilance and phytovigilance spontaneous reports
Serenoa repens is mostly safe but has some risks, especially at high doses or when used with other products for over two weeks.
research Volume 1982, No. 4 February 26, 1982
Some medications caused temporary health issues that improved after stopping the drugs, but two patients died from liver problems linked to carbamazepine.
research Alopecia induced by tumour necrosis factor-alpha antagonists: description of 52 cases and disproportionality analysis in a nationwide pharmacovigilance database
Some drugs used to treat inflammation may cause hair loss.
research Evaluating the safety profile of α-1 blockers, 5α-reductase inhibitors, and PDE5I for BPH: a disproportionality analysis of real-world adverse events based on FDA adverse event reporting system (FAERS)
These medications for BPH have known risks and may have new side effects.
research Exploring the Potential Routine Use of Electronic Healthcare Record Data to Strengthen Early Signal Assessment in UK Medicines Regulation: Proof-of-Concept Study
Using electronic health records can help identify drug side effects but has some limitations.
research Case report: NUDT15 polymorphism and severe azathioprine-induced myelosuppression in a young Chinese female with systematic lupus erythematosus: a case analysis and literature review
Genetic screening for NUDT15 polymorphisms is crucial for patients taking azathioprine, especially in Asians.
research Adverse Cutaneous Reactions to Mood Stabilizers
Mood stabilizers can cause serious skin reactions; careful monitoring and immediate treatment are crucial.
research Oral finasteride use and sexual adverse events: signal detection from disproportionality analyses of data from the United States Food and Drug Administration Adverse Event Reporting System
Oral finasteride may cause more sexual side effects than expected, possibly due to negative publicity and reporting bias.
research Effect of adenosine triphosphate on ribociclib-induced skin toxicity in rats
research Risk assessment of the top 60 drugs for drug-related sexual dysfunction: a disproportion analysis from the Food and Drug Administration adverse event reporting system
Finasteride, dutasteride, and silodosin have the highest risk for causing sexual dysfunction.
research Prevalence and Partern of Early Adverse Reactions in Cancer Patients Receiving Chemotherapy at Ocean Road Cancer Institute
Early detection of chemotherapy side effects allows treatment adjustments, improving patient outcomes.
research Finasteride toxicity information: “limited”, “poor quality”, “biased”
Finasteride toxicity information is limited, poor quality, and biased.
research A Systematic Review of the Cutaneous Adverse Effects of GLP-1 Agonists
research Mining and analysis of adverse event signals of isotretinoin based on the real-world data of FAERS database
Isotretinoin has many serious side effects, including some new ones, needing better safety measures and updated labels.
research No Association between Patient Demographics and Adverse Effects of Low-Dose Oral Minoxidil in a Retrospective Cohort study of Nonscarring Alopecia Patients
research Etoricoxib
A man had a rare skin reaction from a hair loss medication, which improved after stopping the drug.
research Updated Integrated Safety Analysis of Ritlecitinib Over 72 Months In Patients With Alopecia Areata From the ALLEGRO Clinical Trial Program
Ritlecitinib is generally safe for alopecia areata patients over 72 months.
research Faculty Opinions recommendation of Adverse Event Reporting in Clinical Trials of Finasteride for Androgenic Alopecia: A Meta-analysis.
The safety of the hair loss drug finasteride is unclear due to inadequate reporting in clinical trials.
research Delayed onset perforating folliculitis associated with sorafenib
Sorafenib can cause delayed skin problems, so patients need careful monitoring.
research 26-SNP Panel Aids Guiding Androgenetic Alopecia Therapy and Provides Insight into Mechanisms of Action
Genetic profiling can improve androgenetic alopecia treatment by predicting drug response and minimizing side effects.
research Updated Integrated Safety Analysis of Ritlecitinib up to ~5 Years in Adolescents With Alopecia Areata From the ALLEGRO Clinical Trials
Ritlecitinib is generally safe for adolescents with alopecia areata over 5 years.
research Risk of Autoimmune Skin Diseases Associated With Immune Checkpoint Inhibitors: A Pharmacovigilance Analysis Using the FAERS Database
Immune checkpoint inhibitors can increase the risk of autoimmune skin diseases, especially bullous pemphigoid.
research Dermatological drugs, topical agents, and cosmetics
Natural products like propolis are causing more skin allergies, and certain skin treatments and medications have various side effects and risks.
research Toxicity profile of antibody-drug conjugates in breast cancer: practical considerations
ADCs can effectively treat breast cancer but may cause side effects like nausea and hair loss.
research The utility of the classification tools in National Institute of Health and Clinical Excellence’s Clinical Knowledge Summaries for primary care
Nearly half of the classification tools in the National Institute of Health and Clinical Excellence's Clinical Knowledge Summaries might not effectively guide management for general practitioners.